RWE in Gene Therapy: Payer Views

RWE in Gene Therapy: Payer Views

How to harness RWE to win payer support for gene therapies

Gene therapy developers are looking beyond rare diseases to treat a broader range of conditions. While payers are positive for new therapies that treat unmet clinical need there is a growing anxiety: can the cost of these novel therapies be afforded and justified? Payers want real-world evidence (RWE) that informs their decision making, but what evidence, where can it be found and what action can pharma take? This report explores why RWE will increasingly play a critical role in payer assessment of gene therapies and the practical strategies pharma can implement.

Companies

Amgen, Novartis, GlaxoSmithKline, Janssen Biotech, Bristol Myers Squibb, Biogen, Spark Therapeutics, BioMarin Pharmaceutical, Bluebird Bio, CSL Behring, AveXis, Kite Pharma, uniQure, PTC Therapeutics, Celgene, Juno Therapeutics, Orchard Therapeutics